In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that ...
New York partner joins from Paul Weiss, bringing expertise in litigation and AI-related risk, regulations, and governance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback